Acadia reported Q4 2025 GAAP total revenues of USD 284 million and product sales, net of USD 284 million. Nuplazid delivered Q4 2025 GAAP net product sales of USD 174 million (non-GAAP adjusted net sales: USD 189 million, +17.0%), reflecting the first Inflation Reduction Act inflation cap rebate invoices and a USD 20 million change in estimate to Nuplazid IRA rebate accruals recorded in 2025. Daybue generated Q4 2025 net product sales of USD 110 million (+13.0%). Q4 2025 R&D expense was USD 85 million and SG&A expense was USD 156 million. For FY 2025, Acadia reported GAAP total revenues of USD 1.07 billion and net income of USD 391 million (USD 2.30 per diluted share). FY 2025 GAAP net product sales were USD 680 million for Nuplazid and USD 391 million for Daybue. Non-GAAP adjusted total revenues were USD 1.08 billion (+14.0%), and non-GAAP adjusted Nuplazid net sales were USD 692 million (+15.0%). Cash, cash equivalents and investment securities totaled USD 820 million at December 31, 2025. Business updates included a strategic expansion of Nuplazid customer-facing teams with a 30% increase in representatives implemented in early 2026, Daybue STIX shipping to the first patient ahead of a planned broader launch in early Q2 2026, and Phase 2 top-line results for remlifanserin in Alzheimer’s disease psychosis expected between August and October 2026. Acadia guided for FY 2026 (GAAP) total revenues of USD 1.22 billion to USD 1.28 billion, including Nuplazid net product sales of USD 760 million to USD 790 million and Daybue net product sales of USD 460 million to USD 490 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225334279) on February 25, 2026, and is solely responsible for the information contained therein.